Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250783 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL31066883 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL31066868 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL9131907 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL17217520 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL31066870 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL8368647 | 0.98 | ALDH1A1 (0.45) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL252415 | 0.93 | CYP2D6 (0.44) | ALDH1A1CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL22106056 | 0.92 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP1A2TSHRHTT | |
| SCHEMBL22106055 | 0.92 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP1A2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640641-B2 | Curable coating compositions of silane functional polymers | KING INDUSTRIES (US) | 2020-05-05 | — | — | US | claimed |
| US-20200062953-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES | 2020-02-27 | — | — | US | claimed |
| WO-2019157357-A1 | PROCESSES FOR PREPARING CALIXARENES | SI GROUP, INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-20190248721-A1 | PROCESSES FOR PREPARING CALIXARENES | SI GROUP, INC. | 2019-08-15 | — | — | US | claimed |
| US-10336863-B2 | Curable composition having a special catalyst/softner system | HENKEL AG & CO. KGAA (DE) | 2019-07-02 | — | — | US | claimed |
| US-20180237635-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES | 2018-08-23 | — | — | US | claimed |
| US-9976028-B2 | Curable coating compositions of silane functional polymers | KING INDUSTRIES (US) | 2018-05-22 | — | — | US | claimed |
| US-9944593-B2 | Process for the synthesis of fluoralkyl sulfonate salts | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2018-04-17 | — | — | US | claimed |
| EP-1930376-B2 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2016-09-07 | — | — | EP | claimed |
| WO-2016137881-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES (US) | 2016-09-01 | — | — | WO | claimed |
| US-20160244606-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES | 2016-08-25 | — | — | US | claimed |
| WO-2012036392-A3 | HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME | 주식회사 아이지세라피 (KR) | 2012-05-10 | — | — | WO | claimed |
| EP-1930376-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2011-12-07 | — | — | EP | claimed |
| US-8013080-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-09-06 | — | — | US | claimed |
| EP-4692247-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4692148-A1 | CURABLE COMPOSITION AND CURED PRODUCT OF SAME | DIC Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022211-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-1992665-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1990370-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1930376-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248721-A1 | PROCESSES FOR PREPARING CALIXARENES | CALU, CALD1, CALR | ALDH1A1 254/4885CYP2D6 1274/4885MEN1 4829/4885 |
| US-20260022211-A1 | CURABLE COMPOSITION | H1-4, H1-0, H1-2 | ALDH1A1 2939/4885CYP2D6 3557/4885MEN1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.